Abstract
To the Editor,
We would like to share ideas on the publication “Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.” 1 There was no discernible difference in the composite result between patients who received tocilizumab or baricitinib for the treatment of COVID-19, according to Reid et al. However, compared with those taking baricitinib, those receiving tocilizumab experienced higher rates of thrombosis. Larger prospective, randomized trials must be conducted to corroborate these findings. 1 We both concur that there may be clinical applications for tocilizumab or baricitinib. However, it is critical to be aware of any potentially confusing factors. It is difficult to entirely rule out the effects of medication, individual illness, and comorbidity. In addition, the preceding asymptomatic COVID-19 must be considered. It is crucial to consider the fact that COVID-19 is commonly asymptomatic when assessing the efficacy of medical treatment. 2
Footnotes
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The authors received no financial support for the research, authorship, and/or publication of this article.
